Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

David M. Fleischer†1, Scott Sicherer†2, Matthew Greenhawt†3, Dianne Campbell†4, Edmond S. Chan†5‡, Antonella Muraro†6, Susanne Halken†6, Yitzhak Katz†7, Motohiro Ebisawa†8, Lawrence Eichenfield†9, Hugh Sampson†10, FOR THE LEAP TRIAL TEAM and SECONDARY CONTRIBUTORS

Abstract
The purpose of this brief communication is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early rather than delayed peanut introduction during the period of complementary food introduction in infants. This document serves to better inform the decision-making process for healthcare providers regarding such potential benefits of early peanut introduction. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases – sponsored Working Group and the European Academy of Allergy and Clinical Immunology.

Keywords: Allergy prevention, Complementary feeding, Peanut allergy

Introduction and rationale
Peanut allergy is an increasingly troubling global health problem affecting between 1% and 3% of children in many westernized countries. Although multiple methods of measurement have been used and specific estimates differ, there appears to be a sudden increase in the number of cases in the past 10- to 15-year period, suggesting that the prevalence might have tripled in some countries, such as the United States. Extrapolating the currently estimated prevalence, this translates to nearly 100,000 new cases annually (in the United States and United Kingdom), affecting some 1 in 50 primary school-aged children in the United States, Canada, the United Kingdom, and Australia. A similar rise in incidence is now being noted in developing countries, such as Ghana [1–6].

The purpose of this brief communication is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early rather than delayed peanut introduction during the period of complementary food introduction in infants. A recent study, entitled “Randomized trial of peanut consumption in infants at risk for peanut allergy” demonstrated a successful 11% to 25% absolute reduction in the risk of peanut allergy in high-risk infants (and a relative risk reduction of up to 80%) if peanut was introduced between 4 and 11 months of age [7]. In light of the significance of these findings, this document serves to better inform the decision-making process for healthcare providers regarding such potential benefits of early peanut introduction. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Working Group and the European Academy of Allergy and Clinical Immunology (EAACI),...
and thus this document should be considered as interim guidance.

**Summary of new evidence**

In the Learning Early About Peanut Allergy (LEAP) trial, 640 high-risk United Kingdom infants (See Box 1) between the ages of 4 to 11 months were randomized to consume peanut products at least three times a week (6 g of peanut protein; equivalent to 24 g peanuts or 3 teaspoons of peanut butter per week) or to completely avoid peanut products for the first 5 years of life. This included 542 infants found to have negative skin prick test (SPT) responses to peanut at study entry, and 98 infants with SPT wheal diameters to peanut of between 1 and 4 mm (minimally positive SPT response) at study entry. An additional 76 children were excluded from study entry before randomization based on an SPT response of greater than 5 mm, which was assumed to result in a very high likelihood of reacting to a peanut challenge. In an intention-to-treat analysis, 17.2 % in the peanut avoidance group compared to 3.2 % in the peanut consumption group had food challenge-proved peanut allergy by age 5 years, corresponding to a 14 % absolute risk reduction, a number needed to treat (NNT, eg, number of persons needed to be treated for one to receive benefit) of 7.1, and a relative risk reduction of 81 % [7].

When examined in further detail, the isolated beneficial effects for both the primary and secondary prevention of peanut allergy translated to an NNT of 8.5 among the infants with negative SPT responses and an NNT of 4 among the infants with minimally positive SPT responses. Secondary analyses also showed similar levels of prevention in white, black and Asian (Indian and Pakistani) children. Overall, the risk of early introduction in this group was low: 7 of the 319 children randomized to the consumption group reacted to peanut at the baseline food challenge, suggesting that peanut food challenges and introduction, even in infants with minimally positive SPT responses, are safe and feasible. Six children in the consumption group had peanut allergy during the study, indicating that peanut allergy can still develop despite attempts at primary and secondary prevention. Finally, the LEAP trial only included high-risk infants with a minimal or negative SPT response to peanut and therefore does not address a strategy for those without these risk factors for peanut allergy [7].

**How does the LEAP trial affect present guidance for early complementary feeding practices?**

Existing guidelines pertaining to the early introduction of complementary foods have indicated that the introduction of highly allergenic foods, such as peanut, need not be delayed past 4 or 6 months of life. However, they do not actively recommend introduction of peanut between 4 and 6 months of age in high-risk infants, and some of these guidelines specify that certain infants considered at high risk for allergic disease are recommended to first consult an expert [8–14].

The LEAP data provide Level 1 evidence that the practice of early peanut introduction is safe and effective in selected high-risk infants. This study is the first prospective, randomized trial of early peanut intervention and informs provider decision-making regarding high-risk infants, including those already having a positive peanut SPT response but not yet clinically reactive, to receive the benefits noted in the LEAP trial, which might reduce the risk of peanut allergy up to 80 %.

Of note, since children with lesser risk factors for peanut allergy were excluded from enrollment in the LEAP trial, there are no prospective, randomized data investigating the benefit or risk of early peanut introduction in the general to low-risk populations. Consequently, this communication’s guidance is limited to applying the findings of the LEAP trial to other similar high-risk children in more diverse settings around the world. However, multiple guidelines have not recommended delaying allergen introduction in the general to low-risk populations.

**Interim guidance regarding early peanut introduction**

Based on data generated in the LEAP trial and existing guidelines, the following interim guidance is suggested to assist the clinical decision-making of health care providers:

- There is now scientific evidence (Level 1 evidence from a randomized controlled trial) that healthcare providers should recommend introducing peanut-containing products into the diets of “high-risk” infants early on in life (between 4 and 11 months of age) in countries where peanut allergy is prevalent because delaying the introduction of peanut can be associated with an increased risk of peanut allergy.
- Infants with early-onset atopic disease, such as severe eczema, or egg allergy in the first 4 to 6 months of life (see Box 1 for example LEAP criteria), might benefit from evaluation by an allergist or physician trained in management of allergic diseases in this age group to diagnose any food allergy and assist in implementing these suggestions regarding the appropriateness of early peanut introduction. Evaluation of such patients might consist of performing peanut skin testing, in-office observed peanut ingestion, or both, as deemed appropriate after discussion with the family. The clinician can perform an observed peanut challenge for those with evidence of a positive
peanut skin test response to determine whether they are clinically reactive before initiating at-home peanut introduction. Both such strategies were used in the LEAP trial protocol.

- Adherence in the LEAP trial was excellent (92 %), with infants randomized to consume peanut ingesting a median of 7.7 g peanut protein (interquartile range: 6.7 – 8.8 g) per week during the first 2 years of the trial compared with a median of 0 g in the avoidance group (see Box 2 for examples of peanut-containing foods used in the LEAP trial). Although the outcome of the LEAP regimen was excellent, the study does not address use of alternative doses of peanut protein, minimal length of treatment necessary to induce the tolerogenic effect, or potential risks of premature discontinuation or sporadic feeding of peanut.

**Rationale for evaluating and applying this policy to a high-risk population**

The LEAP trial demonstrates that early peanut introduction can be successfully carried out in a high-risk population, such as the population defined in the LEAP trial. However, without intervention by health care providers, there is the potential that such high-risk infants will remain at risk for delayed introduction of solids and allergenic foods into their diet because of the widespread belief that such foods may exacerbate eczema. There will be more extensive guidelines in the near future from the NIAID Working Group and EAACI Guidelines Group with their multidisciplinary stakeholders. These groups will consider all the available data and determine whether there is sufficient evidence to apply prevention strategies to the general population. However, engagement of the primary care, allergy, and dermatology communities to rapidly implement these findings and change the culture of early feeding practices is essential, and the forthcoming NIAID Working Group’s and EAACI Guidelines Group’s documents will better clarify a best-practices approach.

**Abbreviations**

LEAP: Learning Early about Peanut Allergy; NIAID: National Institute of Allergy and Infectious Diseases; EAACI: European Academy of Allergy and Clinical Immunology; SPT: Skin prick test; ITT: Intention-to-treat; NNT: Number needed to treat.

**Competing interests**

The authors declare they have no competing interests associated with this document.

**Authors’ contribution**

We would like to acknowledge Primary Contributors: David M. Fleischer, MD; Scott Sicherer, MD; Matthew Greenhawt, MD; Dianne Campbell, MB BS FRACP PhD; Edmond S. Chan, MD; Antonella Muraro, MD, PhD; Susanne Halken, MD; Yitzhak Katz, MD; Motohiro Ebisawa, MD, PhD; Lawrence Eichenfield, MD; Hugh Sampson, MD; For the LEAP Trial Team: Gideon Lack, MB, BCh; George Du Toit, MB, BCh; Graham Roberts, DM; Henry Bahnson, MPH; and the Secondary Contributors: Jonathan Hourihane, MD, Jonathan
Spiegel, MD, PhD, Michael Young, MD; Amal Assa‘ad, MD; Katrina Allen, BMEdSc MB BS FRACP PhD, Susan Prescott, BMEdSc MB BS FRACP PhD; Sandeep Kapur, MD; Hirohisa Saito, MD, PhD; Ioana Agache, MD, Cezmi A. Akdis, MD, PhD; Hassan Arshad, MD, Kirsten Beyer, MD, Anthony Dubois, MD, Philippe Eigenmann, MD, Monserrat Fernandez-Rivas, MD, Kate Grimshaw RD PhD, Karin Hoffmann-Sommergruber, PhD, Arne Host, MD, Susanne Lau MD, Liam O’Mahony, MD, Clare Mills, PhD; Nikolaos Papadopoulos, MD, Carina Venter, BSc, PhD; Nancy Agmon-Levin, MD, Aharon Kessel, MD, Richard Antaya, MD, Beth Drolet, MD, Lanny Rosenwasser, MD Published on behalf of the American Academy of Allergy, Asthma & Immunology; American Academy of Pediatrics; American College of Allergy, Asthma & Immunology; Australasian Society of Clinical Immunology and Allergy; Canadian Society of Allergy and Clinical Immunology; European Academy of Allergy and Clinical Immunology; Israel Association of Allergy and Clinical Immunology; Japanese Society for Allergy and Clinical Immunology; Korean Society for Allergology; Society for Pediatric Dermatology; and World Allergy Organization. Copublished in the Journal of Allergy and Clinical Immunology; the Annals of Allergy, Asthma and Immunology; Allergy, Asthma & Clinical Immunology; and the World Allergy Organization Journal. All authors read and approved the final manuscript.

Acknowledgements

FOR THE LEAP TRIAL TEAM

Gideon Lack1,2, George Du Toit3, Graham Roberts5, Henry Bahnson1,3, Mary Feeney1,3

SECONDARY CONTRIBUTORS

Jonathan Hourihane1, Jonathan Spiegel1, Michael Young1; Amal Assa‘ad1,2, Katrina Allen2, Susan Prescott4, Sandeep Kapur5; Hirohisa Saito6, Ioana Agache5, Cezmi A. Akdis7, Hassan Arshad8, Kirsten Beyer8, Anthony Dubois9, Philippe Eigenmann10, Monserrat Fernandez-Rivas11, Kate Grimshaw12, Karin Hoffmann-Sommergruber13, Arne Host14, Susanne Lau15, Liam O’Mahony16, Clare Mills16, Nikolaos Papadopoulos17, Carina Venter18, Nancy Agmon-Levin19, Aharon Kessel1, Richard Antaya2, Beth Drolet20, Lanny Rosenwasser20

American Academy of Allergy, Asthma & Immunology (AAAAI), Milwaukee, WI, United States of America
American Academy of Pediatrics (AAP), Chicago, IL, United States of America
American College of Allergy, Asthma & Immunology (ACAAI), Chicago, IL, United States of America
Australasian Society of Clinical Immunology and Allergy (ASCIA), Brookvale, NSW, Australia
Canadian Society of Allergy and Clinical Immunology (CSACI), Orleans, ON, Canada
European Academy of Allergy and Clinical Immunology (EAACI), Zurich, Switzerland
Israel Association of Allergy and Clinical Immunology (IAACI), Tel-Hashomer, Israel
Japanese Society for Allergology (JSA), Tokyo, Japan
Society for Pediatric Dermatology (SPD), Indianapolis, IN, United States of America
World Allergy Organization (WAO), Milwaukee, WI, United States of America
Rho Federal Systems Division Inc., Chapel Hill, NC, United States of America

Author details

1 American Academy of Allergy, Asthma & Immunology (AAAAI), Milwaukee, WI, USA
2 American Academy of Pediatrics (AAP), Chicago, IL, USA
3 American College of Allergy, Asthma, and Immunology (ACAAI), Chicago, IL, USA
4 Australasian Society of Clinical Immunology and Allergy (ASCIA), Brookvale, Australia
5 Canadian Society of Allergy and Clinical Immunology (CSACI), Orleans, ON, Canada
6 European Academy of Allergy and Clinical Immunology (EAACI), Zurich, Switzerland
7 Israel Association of Allergy and Clinical Immunology (IAACI), Tel-Hashomer, Israel
8 Japanese Society for Allergology (JSA), Tokyo, Japan
9 Society for Pediatric Dermatology (SPD), Indianapolis, IN, USA
10 World Allergy Organization (WAO), Milwaukee, WI, USA

Received: 9 June 2015 Accepted: 10 June 2015

Published online: 03 August 2015

References
